American Journal of Ophthalmology
Volume 146, Issue 6 , Pages 935-941.e1 , December 2008

Combined Intravitreal Bevacizumab and Photodynamic Therapy for Retinal Angiomatous Proliferation

  • Masaaki Saito

      Affiliations

    • Department of Ophthalmology, Fukushima Medical University School of Medicine, Fukushima, Japan
    • Corresponding Author InformationInquiries to Masaaki Saito, Department of Ophthalmology, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima 960-1295, Japan
    • ,
  • Chieko Shiragami

      Affiliations

    • Department of Ophthalmology, Kagawa University, Kagawa, Japan
    • ,
  • Fumio Shiraga

      Affiliations

    • Department of Ophthalmology, Kagawa University, Kagawa, Japan
    • ,
  • Dai Nagayama

      Affiliations

    • Department of Ophthalmology, Fukushima Medical University School of Medicine, Fukushima, Japan
    • ,
  • Tomohiro Iida

      Affiliations

    • Department of Ophthalmology, Fukushima Medical University School of Medicine, Fukushima, Japan

,Accepted 30 June 2008.

References 

  1. Yannuzzi LA, Negrão S, Iida T, et al. Retinal angiomatous proliferation in age-related macular degeneration. Retina. 2001;21:416–434
  2. Freund KB, Ho IV, Barbazetto IA, et al. Type 3 neovascularization: the expanded spectrum of retinal angiomatous proliferation. Retina. 2008;28:201–211
  3. Bottoni F, Massacesi A, Cigada M, Viola F, Musicco I, Staurenghi G. Treatment of retinal angiomatous proliferation in age-related macular degeneration: a series of 104 cases of retinal angiomatous proliferation. Arch Ophthalmol. 2005;123:1644–1650
  4. Bressler NM. Retinal anastomosis to choroidal neovascularization: a bum rap for a difficult disease. Arch Ophthalmol. 2005;123:1741–1743
  5. Slakter JS, Yannuzzi LA, Schneider U, et al. Retinal choroidal anastomoses and occult choroidal neovascularization in age-related macular degeneration. Ophthalmology. 2000;107:742–753
  6. Kuroiwa S, Arai J, Gaun S, Iida T, Yoshimura N. Rapidly progressive scar formation after transpupillary thermotherapy in retinal angiomatous proliferation. Retina. 2003;23:417–420
  7. Sakimoto S, Gomi F, Sakaguchi H, Tano Y. Recurrent retinal angiomatous proliferation after surgical ablation. Am J Ophthalmol. 2005;139:917–918
  8. Shiragami C, Iida T, Nagayama D, Baba T, Shiraga F. Recurrence after surgical ablation for retinal angiomatous proliferation. Retina. 2007;27:198–203
  9. Boscia F, Furino C, Sborgia L, Reibaldi M, Sborgia C. Photodynamic therapy for retinal angiomatous proliferations and pigment epithelium detachment. Am J Ophthalmol. 2004;138:1077–1079
  10. Silva RM, Faria de Abreu JR, Travassos A, Cunha-Vaz JG. Stabilization of visual acuity with photodynamic therapy in eyes with chorioretinal anastomoses. Graefes Arch Clin Exp Ophthalmol. 2004;242:368–376
  11. Boscia F, Parodi MB, Furino C, Reibaldi M, Sborgia C. Photodynamic therapy with verteporfin for retinal angiomatous proliferation. Graefes Arch Clin Exp Ophthalmol. 2006;244:1224–1232
  12. Panagiotidis D, Karagiannis DA, Baltatzis S. Photodynamic therapy in retinal angiomatous proliferation stage I. Eur J Ophthalmol. 2006;16:326–329
  13. Silva RM, Cachulo ML, Figueira J, de Abreu JR, Cunha-Vaz JG. Chorioretinal anastomosis and photodynamic therapy: a two-year follow-up study. Graefes Arch Clin Exp Ophthalmol. 2007;245:1131–1139
  14. Freund KB, Klais CM, Eandi CM, et al. Sequenced combined intravitreal triamcinolone and indocyanine green angiography-guided photodynamic therapy for retinal angiomatous proliferation. Arch Ophthalmol. 2006;124:487–492
  15. Van de Moere A, Kak R, Sandhu SS, Talks SJ. Anatomical and visual outcome of retinal angiomatous proliferation treated with photodynamic therapy and intravitreal triamcinolone. Am J Ophthalmol. 2007;143:701–704
  16. Reche-Frutos J, Calvo-Gonzalez C, Donate-Lopez J, et al. Retinal angiomatous proliferation reactivation 6 months after high-dose intravitreal acetonide triamcinolone and photodynamic therapy. Eur J Ophthalmol. 2007;17:979–982
  17. Krebs I, Krepler K, Stolba U, Goll A, Binder S. Retinal angiomatous proliferation: combined therapy of intravitreal triamcinolone acetonide and PDT versus PDT alone. Graefes Arch Clin Exp Ophthalmol. 2008;246:237–243
  18. Spaide RF, Sorenson J, Maranan L. Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization. Ophthalmology. 2003;110:1517–1525
  19. Spaide RF, Sorenson J, Maranan L. Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization. Ophthalmology. 2005;112:301–304
  20. Bhavsar AR, Ip MS, Glassman AR DRCRnet Group, SCORE Study Group. The risk of endophthalmitis following intravitreal triamcinolone injection in the DRCRnet and SCORE clinical trials. Am J Ophthalmol. 2007;144:454–456
  21. Kliffen M, Sharma HS, Mooy CM, Kerkvliet S, de Jong PT. Increased expression of angiogenic growth factors in age-related maculopathy. Br J Ophthalmol. 1997;81:154–162
  22. Krzystolik MG, Afshari MA, Adamis AP, et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol. 2002;120:338–346
  23. Gragoudas ES, Adamis AP, Cunningham ET, Feinsod M, Guyer DR VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351:2805–2816
  24. Spaide RF, Laud K, Fine HF, et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina. 2006;26:383–390
  25. Rosenfeld PJ, Brown DM, Heier JS, et al. MARINA Study Group Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419–1431
  26. Brown DM, Kaiser PK, Michels M, et al. ANCHOR Study Group Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432–1444
  27. Kaiser PK, Blodi BA, Shapiro H, Acharya NR MARINA Study Group. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology. 2007;114:1868–1875
  28. Wu L, Martínez-Castellanos MA, Quiroz-Mercado H, et al. Pan-American Collaborative Retina Group (PACORES) Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol. 2008;246:81–87
  29. Bashshur ZF, Haddad ZA, Schakal A, Jaafar RF, Saab M, Noureddin BN. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study. Am J Ophthalmol. 2008;145:249–256
  30. Leys A, Zlateva G, Shah SN, Patel M. Quality of life in patients with age-related macular degeneration: results from the VISION Study. Eye. 2008;22:792–798
  31. Meyerle CB, Freund KB, Iturralde D, et al. Intravitreal bevacizumab (Avastin) for retinal angiomatous proliferation. Retina. 2007;27:451–457
  32. Joeres S, Heussen FM, Treziak T, Bopp S, Joussen AM. Bevacizumab (Avastin) treatment in patients with retinal angiomatous proliferation. Graefes Arch Clin Exp Ophthalmol. 2007;245:1597–1602
  33. Costagliola C, Romano MR, dell'Omo R, Cipollone U, Polisena P. Intravitreal bevacizumab for the treatment of retinal angiomatous proliferation. Am J Ophthalmol. 2007;144:449–451
  34. Dhalla MS, Shah GK, Blinder KJ, Ryan EH, Mittra RA, Tewari A. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration. Retina. 2006;26:988–993
  35. Ladas ID, Kotsolis AI, Papakostas TD, Rouvas AA, Karagiannis DA, Vergados I. Intravitreal bevacizumab combined with photodynamic therapy for the treatment of occult choroidal neovascularization associated with serous pigment epithelium detachment in age-related macular degeneration. Retina. 2007;27:891–896
  36. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials—TAP Report 1. Arch Ophthalmol. 1999;117:1329–1345
  37. Borrillo JL, Sivalingam A, Martidis A, Federman JL. Surgical ablation of retinal angiomatous proliferation. Arch Ophthalmol. 2003;121:558–561
  38. Lopez PF, Sippy BD, Lambert HM, Thach AB, Hinton DR. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration–related choroidal neovascular membranes. Invest Ophthalmol Vis Sci. 1996;37:855–868
  39. Wells JA, Murthy R, Chibber R, et al. Levels of vascular endothelial growth factor are elevated in the vitreous of patients with subretinal neovascularisation. Br J Ophthalmol. 1996;80:363–366
  40. Tatar O, Adam A, Shinoda K, et al. Expression of VEGF and PEDF in choroidal neovascular membranes following verteporfin photodynamic therapy. Am J Ophthalmol. 2006;142:95–104
  41. Rouvas AA, Papakostas TD, Ladas ID, et al. Enlargement of the hypofluorescent post photodynamic therapy treatment spot after a combination of photodynamic therapy with an intravitreal injection of bevacizumab for retinal angiomatous proliferation. Graefes Arch Clin Exp Ophthalmol. 2008;246:315–318
  42. Michels S, Hansmann F, Geitzenauer W, et al. Influence of treatment parameters on selectivity of verteporfin therapy. Invest Ophthalmol Vis Sci. 2006;47:371–376

PII: S0002-9394(08)00521-7

doi: 10.1016/j.ajo.2008.06.033

American Journal of Ophthalmology
Volume 146, Issue 6 , Pages 935-941.e1 , December 2008

Article Tools

* Image Usage & Resolution